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Abstarct
Introduction: Due to dearth of data, chronic kidney 
disease (CKD) outcome in African children has been 
dismal owing to poor understanding of its etiology, 
manifestations and management. 
Methods: We retrospectively analyzed the records of 
154 CKD children and adolescents who were managed 
at Obafemi Awolowo University Teaching Hospitals 
Complex between 2000 and 2009 to evaluate the 
epidemiology and clinicopathologic outcome of pediatric 
CKD in Nigeria. 
Results: Overall mean incidence was 11 (6-20) per 
million children population (pmcp)/year while prevalence 
averaged 48 (8-101) pmcp. There were 86 males (55.8%). 
Median age was 10.0 (0.2-15.5) years with 83.8% ≥ 5 
years old. Etiologies were glomerular disease (GMD, 
90.26%), congenital and acquired urinary tract (7.79%) 
and hereditary disorders (1.95%). CKD stages at diagnosis 
were 45.5% CKD-1, 22.7% CKD-2, 10.4% CKD-3, 2.6% 
CKD-4 and 18.8% CKD-5. Median progression time 
through the CKD stages was 24.0 (3-108) months. Mean 
dialysis incidence and prevalence were 1 (0-4) pmcp/
year and 4 (1-12) pmcp, respectively. Hypertension, 
heart failure (HF), malnutrition, anemia, acute-on-CKD, 
need for dialysis, azotemia, hypercreatininemia, and 
high calcium-phosphorous product (≥ 55 mg2/dL2) were 
mortality risk factors. CKD-1 survived significantly better 
than CKD stages 3-5 (p < 0.05) but not CKD-2 (p=0.1). 
Hypertensive CKDs without HF survived better (73.0%) 
than hypertensive CKDs with HF (16.0%) [Hazard ratio 
(HR): 0.34, 95% CI: 0.14-0.83]. GMD survived better 
(68.5%) than non-GMD patients (33.0%) [HR: 2.87, 
95% CI: 1.16-7.06]. 
Conclusion: CKD was commoner among school than 
pre-school age children. GMD was the predominant 
etiology with better outcome than non-GMD. 
Comorbidity prevalence increased significantly with 
increasing severity of CKD stage.  
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Introduction
Chronic kidney disease (CKD) is a progressive disorder 
with serious systemic morbidities causing prolonged 
patient sufferings, increased treatment cost, and death 
inspite of much caring effort. Childhood and adolescent 
CKD, especially in its advanced form, poses serious 
cardiovascular, neurologic, metabolic, hematologic, 
endocrine and other varied clinical problems that stretch 
the financial capacity of parents to the limits. CKD 
management burden has increased over the years across 
the globe. The situation is worse in developing countries 
with limited resources [1, 2]. Developed countries with 
adequate resources have registered CKD as a major 
health problem [3-6] with huge financial implications for 
governments [3]. This became a source of concern both to 
the International Society of Nephrology and International 
Federation of Kidney Foundation that it was considered 
imperative to jointly launch a ‘World Kidney Day’ that has 
been held yearly since 2006 [7]. NKF-K/DOQI (National 
Kidney Foundation-Kidney Disease Outcome Quality 
Initiative) has formulated comprehensive CKD clinical 
practice guidelines to promote early disease detection, 
delay disease progression, prevent related complications 
and improve outcome [8]. 
Published K/DOQI-based data on pediatric CKD are 
few [2, 9-20]. Most of them are from centers outside 
Africa [9-20]. At the time of writing only one published 
K/DOQI-based report is from Africa [2]. Dearth of 
information on CKD from Africa has led to dismal 
outcome owing to poor understanding of its etiology, 
clinicopathologic manifestations, leading to late diagnosis 
and management including preventive measures. This 
study sought to expand the available K/DOQI-based 
CKD data from Africa by determining CKD incidence, 
prevalence, etiologies, stages, clinicopathologic 
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manifestations, and outcome in Nigerian children and 
adolescents managed at our center.   
Methods
we performed a retrospective analysis of baseline and 
follow-up data of pediatric CKD patients in the pediatric 
nephrology and hypertension unit, Obafemi Awolowo 
university teaching hospitals complex, ile-ife, Osun 
state, Nigeria. Records between January 1st, 2000 and 
December 31st, 2009 were reviewd. In our locality, the 
population of children and adolescents (≤ 16 years old) 
is 1 530 000. The study was approved by research and 
ethical committee of our institution. 
All patients with laboratory and/ or radiologic evidence 
of CKD, who were followed-up for ≥ 3 months, were 
included. Patients with insufficient laboratory data were 
excluded. Estimated glomerular filtration rate (eGFR) 
was determined using the Schwartz formula [21]. We 
diagnosed CKD based on K/DOQI diagnostic and 
staging criteria [8]. Significant proteinuria was defined 
as a dipstick proteinuria of 1+ or more or ≥4 mg/m2/
hr in a 24-hour urine sample or UPCR ≥ 20 mg/mmol. 
Hematocrit < 33.0% was regarded as anemia. Hospital 
presentions >3 months after onset of symptoms were 
regarded as late presentaions. Hypertension (HTN) was 
defined and staged according to the task force report on 
high blood pressure in children and adolescents [22]. 
Considering that all patients had at least one end-organ 
damage, post treatment control of HTN was regarded 
as good, fair, and poor if systolic and/ or diastolic blood 
pressure (BP) was ≤ 50th percentile,  >50th but < 90th 
percentile, and > 90th percentile for age, gender and 
height, respectively.
Chronic glomerulonephritis markers were hypertension, 
azotemia, reduced eGFR, red blood cell cast, proteinuria, 
hematuria, symmetrically shrunken kidneys on 
ultrasound, and renal histopathologic features. Sickle cell 
anemia nephropathy markers comprised hemoglobin-S 
on electrophoresis, proteinuria with or without urine 
sediments and renal histopathologic features. Long 
standing history of bilateral flank pains, fever, dysuria, 
white blood cell casts and persistently low specific 
gravity on urinalysis, significant bacteriuria, and 
asymmetrically shrunken kidneys on ultrasound indicated 
chronic pyelonephritis. Obstructive uropathies due to 
posterior uritheral valve (PUV) and urinary bladder 
rhabdomyosarcoma were diagnosed based on poor 
urine stream, urinary retention and abnormal voiding 
cystourithrogram (VCUG). Urethrocystoscopy and 
histopathologic features confirmed rhabdomyosarcoma. 
Poor urine stream and stenotic external urethral meatus 
confirmed post circumcision meatal stenosis. Systemic 
lupus erythematosus and Churg-Strauss syndrome 
associated nephropathy was diagnosed using the 
American College of Rheumatology criteria [23, 24]. 
Diagnoses of infant polycystic kidney disease (IPKD), 
solitary multi-cystic dysplastic kidney, and fused crossed 
ectopic kidney were made by ultrasound.   
Because K/DOQI recommendation is not applicable 
to children < 2 years old, the CKD stages for this age 
group was, therefore, computed by applying the same 
percentage reduction of the eGFR from the lower limit 
of normal range for each of the five K/DOQI CKD stages 
to the lower limits of normal eGFR for each of the age 
groups under 2 years (Table-1).    
To analyze data, SPSS Version 15.0 (SPSS Inc., Chicago, 
IL, USA) was used. The comparative statistics used 
were chi-square test, odds ratio (OR), hazard ratio, 
Wilcoxon signed ranks test, Pearson correlation, Cox 
regression analysis, Kaplan-Meier survival analysis and 
the log-rank test. Data of patients who presented with 
CKD-5 and remained so for ≥ 3 months were excluded 
from renal survival analysis. The diagnostic accuracy 
of identified mortality risk factors, including laboratory 
tests, in predicting mortality was determined using the 
AUROC curve test. The sensitivity, specificity, positive 
and negative predictive values as well as the positive and 
negative LR for the categorical mortality risk factors and 
diagnostic (continuous) test variables was calculated. 













lower limit of   
NGFR reduced 
by 66.7-34.4%  
Stage-4 CKD:
lower limit of   
NGFR reduced  
by 83.3-67.8% 
Stage-5 CKD:
lower limit of   
NGFR reduced 
by >83.3% 
1 week 26-56 ≥ 26 17.3-25.7 8.7-17.1 4.3-8.4 <4.3
2-8 weeks 41-91 ≥ 41 27.3-40.5 13.7-26.9 6.8-13.2 <6.8
9  weeks to 2 years 74-118 ≥ 74 49.3-73.2 24.6-48.5 12.0-24.0 <12.0
Table 1: Classification and staging of chronic kidney disease in children < 2 years of age in the studied group
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Cut-point value that most predict mortality for each of 
the diagnostic test variables was determined using the 
Youden’s index [25]. Statistically significant p value was 
set at <0.05.   
Results
Of 8 393 pediatric admissions, 154 (1.83%) had CKD. 
The incidence of chronic kidney disease (CKD) increased 
with increasing incidence of pediatric admission. CKD 
prevalence also increased from year to year (Figure-1). 
Table-2 summarizes the demographic and anthropometric 
characteristics of the patients. 
Table-3 summarizes the CKD etiology pattern while 
Figure-2 shows the prevalence of CKD etiology by age 
group. Disease progression occurred over a median time 
of 24.0 (30.3 ± 3.2; range 3-108) months in 16 patients 
who required no dialysis. Four (2.6%) patients were 
under 2 years of age. One of these was in stage 1 and 
three were in stage 5 CKD, due to rapidly progressive 
glomerulonephritis, infantile polycystic kidney disease 
(IPKD), and PUV (in two cases). Their eGFR ranged 
between two and 82 mL/min/1.73m2. 
Prevalence of major comorbidities by chronic kidney 
disease (CKD) stage is shown in Figure-3. The risk of 
elevated calcium-phosphorous product [odds ratio, OR: 
2.5, 95% CI: 1.76-3.56], malnutrition [OR: 1.74, 95% 
CI: 1.40-2.16], anemia [OR: 2.16, 95% CI: 1.83-2.56], 
hypertension [OR: 2.09, 95% CI: 1.76-2.49], and 
heart failure [OR: 2.24, 95% CI: 1.80-2.81] increased 
significantly from CKD stage 1 to 5.  Other comorbidities 
were water intoxication (n=3), stroke (n=5) and 
hypertensive encephalopathy (n=22). Seven patients 
had varying grades of hypertensive retinopathy. The 
prevalences of malnutrition in social classes II, III, IV 
and V were 12.5%, 28%, 21% and 41.3% respectively. 
Seventeen patients were growth retarded. 
Forty-nine of 121 (40.5%) patients, who survived beyond 
6 months, were lost to follow-up. Median follow-up period 
was 6.0 (16.8 ± 22.6, range: 0.25-127) months. CKD-1 
was significantly associated with better patients’ survival 
than stages 3-5 but not CKD-2 (Figure-4). Renal survival 
at 1 and 5 years were 94.1% and 63.4%, respectively. 
Overall patients’ survival at 1 and 5 years were 80.7% 
and 66.0% respectively. Hypertension (HTN), heart 
failure (HF), Protein energy malnutrition (PEM), anemia, 
superimposed acute kidney injury, need for dialysis, 
azotemia, hypercreatinemia, and high Ca x P (≥ 55 mg2/
dL2) were mortality risk factors. The continuous risk 
factors had similar AUROCs implying that any of the test 
variables can reasonably predict mortality in childhood 
CKD. But low hematocrit cut-point ≤ 22.5% was most 
predictive of mortality with 94% sensitivity, 78% 
specificity, 58.5% positive and 97.5% negative predictive 
value as well as positive LR of 4.3 and negative LR of 
0.1.
Forty-one patients required dialysis but only 17 patients 
were dialyzed (three by peritoneal dialysis and fourteen 
by hemodialysis), giving an overall median dialysis 
incidence and prevalence of one (0-4) pmcp/year and 
four (1-12) pmcp, respectively. Non-dialysis was due 
to financial constraints in 12 patients (50.0%), diuresis 
onset (12.5%), death (12.5%), positive human immune 
deficiency virus testing (8.3%), and other factors (16.7%). 
Eight incident dialysis patients died owing to inability 
to afford further dialysis; similarly, financial constraints 
precluded kidney transplant in the prevalent dialysis 
patients. 
There were 139 patients with glomerular disease (GMD) 
and 15 patients with non-GMD. Median illness duration 
before presentation was two and 48 months for GMD 
and non-GMD, respectively (p= 0.001). Estimated GFR 
at presentation was significantly lower in non-GMD than 
GMD patients (12.4 versus 64 ml/min/1.73m2, p=0.0016). 
One-year renal survival in GMD and non-GMD was 
95.4% and 80.0%, respectively [hazard ratio (HR): 8.12, 
95% CI: 1.44-46.0; p=0.02]. GMD patients (68.5%) 
survived better than non-GMD (33.0%) [HR: 2.87,  95% 
CI: 1.16-7.06; p=0.02].
Half the patients were hypertensive. Blood pressure 
control was good, fair and poor in 56%, 23.4% and 20.6% 
of patients respectively. The number of antihypertensive 
medications used was one, two, three or more in 39%, 
35%, 17% and 9% respectively. By Kaplan-Meier 
pairwise comparisons and the log-rank test, patients with 
good BP control survived (66.7%) better than patients 
Figure-1: The yearly incidence and prevelance of CKD in 
the studied population
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with either fair (24.1%; p=0.002) or poor (0.0%; p=0.000) 
BP control. Hypertensives with good BP control (66.7%) 
and normotensives (90.4%) survived similarly, p= 0.2. 
Normotensives survived (90.4%) better than patients 
with either stage I (46.8%, p=0.01) or stage II (49.3%, 
p=0.000) HTN. Stages 1 and 2 HTN patients survived 
similarly (p=0.4). Cox regression analysis revealed a 
55.5% (6/13) cumulative mortality rate among non-
hypertensive HF compared with 2.4% (1/63) in patients 
without HF and HTN (HR: 0.16, 95% CI: 0.07-0.37; 
p=0.000). The cumulative mortality in patients with both 
HTN and HF was 84.0% (17/33) compared with 27.0% 
(7/43) in hypertensives without HF (HR: 0.34, 95% CI: 
0.14-0.83; p=0.02). 
Normotensives demonstrated significantly higher one/
five years renal survival (97.0/80.0%) than patients 
with fair (75.0/25.0%, p= 0.01) and poor (50.0/0.00%, 
p=0.003) BP control. Normotensives (97.0/80.0%) and 
hypertensives with good BP control (96.2/63.0%, p=0.4) 
had similar one/five years renal survival. Median renal 
survival times of patients who received either angiotensin 
antagonist medications (ACEi or ARB) or patients treated 
with other anti-hypertensives were similar (47 versus 33 
months; p=0.6). 
Discussion
Mean CKD incidence in our center increased from 3.43 
to 11 pmcp/year, three times more, from 1995-1999 
[1] to 2000-2009 eras, emphasizing the importance of 
prevention. Other centers have observed similar rising 
incidence of CKD (8-14.3 pmcp/year) [18, 19, 26-29] and 
massive increase in CKD prevalence (49.0-96.1 pmcp) 
[18, 19, 26-29]. The increased  prevalence (48.0 pmcp) 
observed in this study concurs with the rising global CKD 
burden. This, in our setting, calls for facility expansion if 
qualitative patients care is not to be compromised. CKD 
stages prevalence pattern vary from study to study [2, 9, 
10, 13, 18, 19]. Our results show the dynamic nature of 
CKD with sixteen patients progressing through the stages 
without needing dialysis while seventeen progressed 
to ESRD and received  dialysis. At diagnosis CKD-5 
constituted 18.8% of the entire CKD stage spectrum 
agreeing with the statement that, ‘CKD-5 represents the 
tip of CKD iceberg’ [6]. 
In most studies, about 56.3-86.8% of the patients were 
aged 5 years and above [2, 12, 26, 30-33] with average 
diagnosis age being 6.9-11.29 years [2, 9, 12, 29-34]. Our 
findings did not contradict this global CKD age trend 
suggesting that CKD is commonly a school age disease. 
Non-GMDs, largely due to congenital anomalies of the 
kidney and urinary tract (CAKUT) and non-CAKUT, 
were not diagnosed during infancy in majority of our 
Table 2: Demographic and clinical characteristics of studied 
patients (N=154)
Demographic and clinical 
characteristics of studied patients
Results
Overall paediatric admission incidence,  
pmcp/year (N [range])
549 [391-959] 
Overall mean CKD incidence, 
pmcp/year (N [range])
11 [6-20]
Overall mean CKD prevalence, 
pmcp (N [range])
48 [8-101]
CKD incidence at diagnosis (pmcp/year)
     CKD stage 1 5
     CKD stage 2 3
     CKD stage 3 2
     CKD stage 4 1
     CKD stage 5 2
CKD prevalence at diagnosis (pmcp)
     CKD stage 1 46
     CKD stage 2 23
     CKD stage 3 11
     CKD stage 4 3
     CKD stage 5 19
Socioeconomic class [N (%)]
     II 8 (5.2)
     III 18 (11.7)
     IV 24 (15.6)
     V 104 (67.5)
Late presentation (N (%) 71 (46.1)
Pre-diagnosis duration of illness symptoms, 
months (median [range])
3.0 [0-132]
Male gender, (N (%)) 86 (55.8)
Age, years (mean ± SD) 9.2 ± 3.7
Age group, years (N (%))
     < 5 20 (13.0)
     5-9 53 (34.4)
     10-14 76 (49.4)
     15-19 5 (3.2)
Weight , kg (mean ± SD) 27.7 ± 10.6
Height, cm (mean ± SD) 127.3 ± 19.7
Body mass index, kg/m2 (mean ± SD) 17.0 ± 3.6
CKD: chronic kidney disease; pmcp: per million children population
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patients. The peak age groups at diagnosis of IPKD, 
and CAKUT/non-CAKUT in this study were 5-9 years 
and 10-14 years, respectively. This contradicts the age 
group pattern in European countries where diagnoses 
and treatment of these conditions are commonly made 
during infancy [10, 19]. Poorer renal and  patients’ 
survival in non-GMD compared with GMD patients was 
significantly due to severer renal function impairment 
at diagnosis, late hospital presentation and management 
in the former. This explains why mortality risk was 
approximately three times higher in non-GMD than GMD 
patients. Elsewhere, non-GMD survived better than GMD 
because of early diagnosis and treatment [29]. These facts 
underline the need for deliberate prenatal and neonatal 
screening for CAKUT in Nigeria for early diagnosis, 
management and better outcome. Unlike in Australia/
New Zealand, Turkey, Canada and some European 
countries, where non-GMD predominantly cause CKD 
(67.5-97.0%) [9, 10, 12, 18, 19, 26, 28, 29], GMD was 
the predominant etiology in our patients (90.3%) and 
other centers in Nigeria and some developing countries 
[2, 31, 33, 34]. High prevalence of bacterial, viral, and 
parasitic infections that commonly affect the kidneys 
in developing countries was considered responsible for 
this [35]. The low ESRD burden in this study emanated 
from our extremely low incidence and prevalence rates 
Table 3: Pattern of etiology of chronic kidney disease in the studied group
Etiology Number within category (%)
% of total CKD 
patients (N=154)
Primary Glomerular Disease (n=99) 64.29
     Nephrotic syndrome 69 (69.7) 44.80
     Chronic glomerulonephritis (GN) 30 (30.3) 19.50
Secondary Glomerular Disease (n=40) 25.97
     Lupus nephritis 15 (37.5) 9.70
     Hepatitis B virus nephritis 6 (15.0) 3.90
     Sickle cell nephropathy 6 (15.0) 3.90
     Churg-Strauss syndrome nephritis 3 (7.5) 1.95
     Rapidly progressive GN (Henoch-Schonlein purpura) 3 (7.5) 1.95
     Human immune deficiency virus-associated nephropathy 2 (5.0) 1.30
     Bee stings 1 (2.5) 0.65
     Rhabdomyosarcoma (paraneoplastic syndrome)  1 (2.5) 0.65
     Burkitt’s lymphoma nephropathy 1 (2.5) 0.65
     Addison’s disease 1 (2.5) 0.65
     Mixed connective tissue disease 1 (2.5) 0.65
Urinary Tract Disorder (n=12) 7.79
     Posterior urethral valves (PUV) 4 (33.3) 2.60
     Crossed fussed ectopic kidney with severe hypospadias and meatal stenosis  1 (8.35) 0.65
     Solitary dysplastic multicystic kidney with PUV  1 (8.35) 0.65
     Prune Belly syndrome with PUV 1 (8.35) 0.65
     Post circumcision meatal stenosis    4 (33.3) 2.60
     Chronic pyelonephritis 1 (8.35) 0.65
Hereditary (n=3)
     Infantile polycystic kidney disease 3 (100.0) 1.95
CKD: chronic kidney disease
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of renal replacement therapy by dialysis. This is similar 
to findings in Serbian and Vietnamese children [18, 33]. 
Low socio-economic class of the majority of the patients 
largely contributed to this as the burden of  healthcare 
delivery cost is borne totally  by patients in Nigeria. 
The overall prevalence of high Ca x P, a significant 
mortality risk factor in this study, was 15%. This is 
similar to the 27.1% prevalence reported for Turkish 
children [12]. Vascular calcifications have been associated 
with high Ca × P with increased risk of cardiovascular 
morbidity and mortality [37].   
Protein energy malnutrition (PEM) prevalence ranges 
between 6% and 65% in childhood CKD [19, 38]. It is 
more pronounced when dialysis is initiated, because of 
associated increased catabolism, loss of nutrients and 
anti-oxidants, and dietary restrictions [39]. In this study, 
PEM prevalence increased from 32.4% for CKD-1 to 
50% and 41.4% for CKD -4 and -5, respectively. In this 
and another study, PEM was a risk factor for mortality 
[40]. 
An overall 36.6% anemia prevalence rate that increased 
from 31% for CKD-1 to 93.3% for CKD -4 and -5 
was found in Canadian children [9]. A higher overall 
prevalence (58.4%) that increased from 41.4% for 
CKD-1 to 100% for CKD-4 and 97.0% for CKD-5 was 
found in this study. Anemia is associated with increased 
severity of congestive HF, increased hospitalization, 
worse cardiac function and functional class, the need for 
higher doses of diuretics, progressive worsening of renal 
function and reduced quality of life [41].
In childhood CKD, hypertension prevalence may range 
between 20% and 80% depending on degree of renal 
dysfunction and underlying renal disease [42, 43]. About 
50% of our patients were hypertensive with majority 
(70%) having stage 2 HTN. HTN was an independent 
mortality risk factor and was associated with escalation 
of mortality from 55.5% in non-hypertensive HF 
patients to 84% in hypertensive HF patients. Concentric 
left ventricular hypertrophy was a major HTN related 
cardiovascular morbidity in those with echocardiogram 
results. Monotherapy was rarely effective in controlling 
CKD-associated HTN as 61% of our patients were treated 
with two or more anti-hypertensives. Good BP control 
had better renal and patients’ survival than patients with 
either fair or poor BP control. Post-treatment BP in 
hypertensives with good BP control was similar to the 
normotensives’. Furthermore, both had similar renal 
survival, emphasizing the importance of HTN as a risk 
factor for disease progression and the need to tame it 
effectively. 
CKD mortality rate is higher in developing (20.3-58.3%) 
[1, 2, 30-32, 34, 44] than developed countries (3-20.0%) 
[10, 45, 46]. In this study the  five year all-cause cumulative 
mortality is 34.0% , a rate which is considered  high and 
similar to findings in developing countries [2, 30-33]; the 
high mortality rate was sequel to poor dialysis access and 
severe co-morbidities. 
Conclusions
CKD was commoner among school than pre-school age 
children. GMD was the predominant etiology with better 
renal and patient outcome than non-GMD. Comorbidity 
prevalence increased significantly with increasing 
severity of CKD stage.      
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